What is it about?
Due to the high affinity of quinazoline derivatives to over-expressed EGFR in tumor cell lines, researchers have designed some radiotracers of quinazoline derivatives for the diagnosis of tumor diseases. However, these radiotracers encountered some drawbacks in PET imaging due to their high lipophilicity. Therefore, we attempted to develop novel F-18 labeled quinazoline derivatives with low lipophilicity to overcome these shortcomings.
Featured Image
Why is it important?
We successfully synthesized four novel radiotracers with low lipophilicity. From this research, we also concluded that we should control the lipophilicity of the quinazoline radiotracer at a proper level. We should balance the relationship between the specific binding ability to the receptor and the clearance rate in non-target organs and tissue in vivo as well. These conclusions will guide our concept of radiotracer molecular design in future research.
Perspectives
I'm very pleasure to work with my professors and colleagues from Key Laboratory of Radiopharmaceuticals, College of Chemistry, Beijing Normal University. With their unremitting efforts, this article could accepted and finally published on JLCR. I hope this article may enlighten other radiopharmaceuticals researches.
Chong Yan
Read the Original
This page is a summary of: Synthesis and evaluation of novel F-18 labeled quinazoline derivatives with low lipophilicity for tumor PET imaging, Journal of Labelled Compounds, August 2017, Wiley,
DOI: 10.1002/jlcr.3538.
You can read the full text:
Contributors
The following have contributed to this page